Albireo Report Enrollment Completion in P-III (ASSERT) Study of Bylvay (odevixibat) for the Treatment of Alagille Syndrome
- The company reported the completion of patient enrollment in the P-III (ASSERT) study to evaluate the safety & efficacy of Bylvay (120µg/kg/day) vs PBO in 52 patients with ALGS at 35 sites across the EU, North America, Middle East & Asia Pacific. The results are expected to be available at the end of 2022
- The primary efficacy of EPs is a change from baseline in scratching to 6mos. as measured by the Albireo ObsRO & secondary efficacy EPs is a change in serum bile acid levels from baseline to the avg. of 20 & 24wk.
- The company has launched Expanded Access Program (EAP) in the US & EU & provides access to patients treated with Bylvay for ALGS before the product’s approval & reimbursement
Ref: Albireo | Image: Albireo
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.